Steven L Maskin

Suggest Changes
Learn More
PURPOSE To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component of keratoconjunctivitis sicca in patients with delayed tear clearance.(More)